278597-28-7

Basic information

• Product Name: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER;3-(2,6-Dichlorophenyl)-4-carboMethoxy-5-isopropyl-isoxazole;Methyl 3-(2,6-dichlorophenyl)-5-isopropylisoxazole-4-carboxylate;4-Isoxazolecarboxylic acid, 3-(2,6-dichlorophenyl)-5-(1-Methylethyl)-, Methyl ester;Methyl 3-(2,6-dichlorophenyl)-5-
• CAS NO: 278597-28-7
• Molecular Formula: C₁₄H₁₃Cl₂NO₃
• Molecular Weight: 314.16
• Mol File: 278597-28-7.mol

Chemical Properties

• Boiling Point: 427.9 °C at 760 mmHg
• Flash Point: 212.6 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C
• PKA: -6.07±0.50(Predicted)
• CAS DataBase Reference: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(278597-28-7)
• EPA Substance Registry System: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(278597-28-7)

Safety Data

• Hazardous Substances Data: 278597-28-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of various drugs and biologically active molecules. Its unique structure allows it to be a versatile component in the development of new pharmaceuticals.
Used in Therapeutic Applications:
In the field of medicine, 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER is studied for its potential therapeutic properties, including its anti-inflammatory and analgesic effects. These properties make it a candidate for the treatment of various conditions that involve inflammation and pain.
Used in Agricultural Chemistry:
3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER has also been investigated for its potential application in the field of agricultural chemistry. It is considered as a potential agrochemical or pesticide, leveraging its chemical properties to contribute to crop protection and enhancement of agricultural yields.

InChI:InChI=1/C14H13Cl2NO3/c1-7(2)13-11(14(18)19-3)12(17-20-13)10-8(15)5-4-6-9(10)16/h4-7H,1-3H3

Upstream product

• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 

Downstream Products

• 774605-58-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylic acid 
• 1020570-56-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde 
• 700835-81-0 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole 
• 1573119-81-9 4-{[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoyl]amino}benzoic acid 
• 1374961-91-7 methyl 4-{[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoyl]amino}benzoate 
• 933799-64-5 2-chloro-4-{[5-isopropyl-3-(2,6-dichlorophenyl)-isoxazol-4-yl]methoxy}benzoic acid 
• 1573119-83-1 methyl 2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoate 
• 1573119-79-5 3-(2,6-dichlorophenyl)-4-(4'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-78-4 3-(2,6-dichlorophenyl)-4-(2'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-80-8 3-(2,6-dichlorophenyl)-4-(4'-methoxycarbonyl-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-82-0 3-(2,6-dichlorophenyl)-4-(2'-methoxycarbonyl-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 933799-50-9 3-(2,6-dichlorophenyl)-4-(3'-carbomethoxy-2-chloro-stilben-4-yl)-oxymethyl-5-isopropyl-isoxazole 
• 1089660-72-9 (E)-3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid 
• 278597-32-3 3-(2,6-dichlorophenyl)-4-(3'-chloro-4'-formylphenoxy)-methyl-5-isopropyl-isoxazole 

Relevant articles and documents

Optical control of the nuclear bile acid receptor FXR with a photohormone

Herein, we report a photoswitchable modulator for a nuclear hormone receptor that exerts its hormonal effects in a light-dependent fashion. The azobenzene AzoGW enables optical control of the farnesoid X receptor (FXR), a key regulator of hepatic bile aci

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.

Design and Structural Optimization of Dual FXR/PPARδActivators

Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence. The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) δhave been validated as molecular targets to counter NASH. To achieve robust therapeutic efficacy in this multifactorial pathology, combined peripheral PPAR?-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach. We have designed a minimal dual FXR/PPARδactivator scaffold by rational fusion of pharmacophores derived from selective agonists. Our dual agonist lead compound exhibited weak agonism on FXR and PPARδand was structurally refined to a potent and balanced FXR/PPARδactivator in a computer-aided fashion. The resulting dual FXR/PPARδmodulator comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.

Novel isoflavone derivative, preparation method therefor and medicinal use of novel isoflavone derivative

The invention relates to the field of pharmaceutical chemistry, relates to an isoflavone derivative, a preparation method therefor and medicinal use of the novel isoflavone derivative and particularlyrelates to isoflavone derivatives represented by a general formula (I) shown in the description, preparation methods therefor, pharmaceutical compositions containing these compounds and medicinal useof the isoflavone derivatives and the pharmaceutical compositions, particularly use of drugs for preventing or treating hyperlipidemia, type II diabetes, atherosclerosis and non-alcoholic fatty hepatitis.

Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities

Our group has previously reported a series of isoflavone derivatives with antidyslipidemic activity. With this background, a series of isoflavone analogs of GW4064 were designed, synthesized and evaluated the lipid-lowering activity of analogs. As a result, most of compounds significantly reduced the lipid accumulation in 3T3-L1 adipocytes and four of them (10a, 11, 15c and 15d) showed stronger inhibitory than GW4064. The most potent compound 15d exhibited promising agonistic activity for FXR in a cell-based luciferase reporter assay. Meanwhile, 15d up-regulated FXR, SHP and BSEP gene expression and down-regulated the mRNA expression of lipogenesis gene SREBP-1c. Besides, an improved safety profile of 15d was also observed in a HepG2 cytotoxicity assay compared with GW4064. The obtained biological results were further confirmed by a molecular docking study showing that 15d fitted well in the binding pocket of FXR and interacted with some key residues simultaneously.

ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR

It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

A kind of the second aryl amine derivative and its preparation method, pharmaceutical composition and use thereof

The invention provides diarylamide type derivatives having a structure shown as a formula (I) as follows, or pharmaceutically acceptable salts thereof, a preparing method of the derivatives, compositions containing the derivatives and the pharmaceutically acceptable salts, and medicine uses of the derivatives and the pharmaceutically acceptable salts. The diarylamide type derivatives having the structure shown as the formula (I) or the pharmaceutically acceptable salts thereof have antagonistic effects on FXR. Integral animal experiments show that the compounds have effects of decreasing blood sugar and reducing blood fat. The compounds can be used for treating hyperlipidemia and type 2 diabetes mellitus.

Isoxazole carboxamide derivatives as ghrelin receptor modulators

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

FARNESOID X RECEPTOR AGONISTS

The invention relates to a compound of formula (I) useful as an agonist for FXR: wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.

Assays for ligands for nuclear receptors

The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator pepetide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.